Skip to main content
Premium Trial:

Request an Annual Quote

Tripos May Sell Discovery Research Arm to Provid Pharmaceuticals for $2M; Informatics Deal Still Pending

NEW YORK (GenomeWeb News) — Tripos today said it plans to sell its Discovery Research business to Provid Pharmaceuticals in a stock sale worth roughly $2 million.
That price may change, depending on changes in capital, debts, equipment, and facility values, Tripos said. The deal also hinges on Provid’s ability to secure the necessary financing, the company said.
The proposed sale would continue Tripos' plans to liquidate its assets and allow its branches to operate as private entities under other ownership in order to “maximize their potential for future success,” Tripos President and CEO John McAlister said in a statement.
McAlister said Discovery Research will maintain its base in Bude, England, and said the prospective owners plan to retain the unit’s current management and staff.
St. Louis-based Tripos six weeks ago disclosed that it would sell its Discovery Informatics business to Vector Capital, a San Francisco-based private equity firm, for $26.5 million.  
Tripos said at the time it expected the Discovery Informatics deal to finalize sometime in the first quarter of 2007, although today it said it will file a proxy statement with the US Securities and Exchange Commission sometime early this year that will offer more information about the agreement with Vector Capital.  

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.